In Vivo Star Anti-Mouse CD370 / CD47 Bispecific Antibody
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD370 / CD47 Bispecific Antibody(克隆 10B4 / A4) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 CD370(别名 C-type lectin family member 9A 等),适用于功能实验。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD370 / CD47 Bispecific Antibody(克隆 10B4 / A4) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 CD370(别名 C-type lectin family member 9A 等),适用于功能实验。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
513901 | 1 mg | ¥11,865
513902 | 5 mg | ¥40,341
513903 | 25 mg | ¥121,023
Product Details
Product Description|In Vivo Grade Recombinant Anti-mouse CD370 / CD47 Bispecific Antibody
Regulatory Status|RUO
Endotoxin
Storage Conditions|4ºC
Recommended Usage|This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
See All Formats|Clone 10B4 / A4
Background Information
CD370, also known as CLEC9A (C-type lectin domain family 9 member A), is an endocytic receptor found predominantly on a specialized subset of dendritic cells known as CD141⁺ (BDCA3⁺) dendritic cells in humans. These cells play a key role in the immune system by cross-presenting antigens derived from dead or damaged cells on MHC class I molecules, thereby priming cytotoxic CD8⁺ T cell responses. Structurally, CD370 is a type II transmembrane protein that contains an extracellular C-type lectin-like domain and a short cytoplasmic tail with an immunoreceptor tyrosine-based activation motif (ITAM-like) that recruits SYK kinase upon ligand engagement. Functionally, CD370 recognizes actin filaments and other damage-associated molecular patterns (DAMPs) from necrotic cells, allowing dendritic cells to efficiently capture and process antigenic material from dying tissue or tumor cells. This makes CD370 an important target for strategies that seek to enhance antigen presentation and anti-tumor immunity.
CD47, in contrast, is a ubiquitously expressed transmembrane protein that acts as a critical regulator of the innate immune system. Often termed the “don’t eat me” signal, CD47 binds to its receptor, Signal Regulatory Protein Alpha (SIRPα), on macrophages and dendritic cells. This interaction inhibits phagocytosis and promotes immune evasion by preventing the clearance of cells expressing high levels of CD47. Many cancers exploit this pathway by overexpressing CD47, effectively shielding themselves from immune recognition and destruction. Blocking CD47–SIRPα signaling has therefore emerged as a powerful immunotherapeutic strategy to promote the phagocytic clearance of tumor cells and enhance anti-tumor immune activation.
A bispecific antibody targeting both CD370 and CD47 represents an innovative approach that synergizes immune activation with inhibition of immune suppression. By simultaneously binding CD47 on tumor cells and CD370 on dendritic cells, such a molecule could facilitate the efficient uptake and processing of cancer antigens while overcoming the “don’t eat me” brake imposed by CD47 signaling. This dual mechanism would ensure that tumor cell debris is effectively internalized, processed, and presented to T cells, leading to stronger and more durable anti-tumor immune responses. Moreover, focusing activation through CD370⁺ dendritic cells could concentrate the immunologic effects within tumor-draining lymphoid tissues, potentially minimizing systemic toxicities like anemia that can occur with traditional CD47 blockade. Thus, a CD370 × CD47 bispecific antibody could bridge the innate and adaptive immune systems, marking a promising new direction in cancer immunotherapy aimed at amplifying immune recognition and long-term tumor eradication.
Data Sheets
Cat # Size Price Quantity 5139011 mg Add to Cart5139025 mg Add to Cart51390325 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). In Vivo Star Anti-Mouse CD370 / CD47 Bispecific Antibody(513901)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd370-cd47-bispecific-antibody.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Mouse CD370 / CD47 Bispecific Antibody(513901). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd370-cd47-bispecific-antibody.html
@misc{biocsp_item_in_vivo_star_anti_mouse_cd370_cd47_bispecific_antibody,
title = {In Vivo Star Anti-Mouse CD370 / CD47 Bispecific Antibody(513901)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd370-cd47-bispecific-antibody.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源